ConductScience.org, home

Paper33910046

Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance.

Liu Y and 19 others. Cell Metab, 2021. Cited by 327 papers, by iCite.

Cite this record

ConductScience Library. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Papers, record 33910046. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33910046

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance.
PubMed
Journal
Cell Metab
PubMed
Year
2021
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
327
iCite
Relative citation ratio, by iCite
15.9
iCite
Revised in PubMed
2022-02-21
PubMed

Authors20

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu YYi
2Liang GGuanghao
3Xu HHongjiao
4Dong WWenxin
5Dong ZZe
6Qiu ZZhiwei
7Zhang ZZihao
8Li FFangle
9Huang YYue
10Li YYilin
11Wu JJun
12Yin SShenyi
13Zhang YYawei
14Guo PPeijin
15Liu JJun
16Xi JJJianzhong Jeff
17Jiang PPeng
18Han DDali
19Yang CGCai-Guang
20Xu MMMeng Michelle

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Alpha-Ketoglutarate-Dependent Dioxygenase FTOMajor topic
Gene Expression Regulation, NeoplasticMajor topic
Immunologic SurveillanceMajor topic
NeoplasmsMajor topic
Animals
Cell Line, Tumor
Female
Melanoma, Experimental
Mice
Mice, Inbred C57BL

Source PubMed

Download CSV of topics

Cited by242

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 327 citations.

PMIDTitleJournalYearIn PapersSource
42978979Mechanisms by which programmed cell death mediates immune evasion and antitumour immunity in oropharyngeal cancer.Front Cell Dev Biol2026https://conductscience.org/library/papers/42978979PubMed
42975694Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions.Cancer Immunol Immunother2026https://conductscience.org/library/papers/42975694PubMed
42918854Molecular functions, cellular responses and pathological implications of the RNA modification N6-methyladenosine.Nat Rev Mol Cell Biol2026https://conductscience.org/library/papers/42918854PubMed
42864360In vivo CRISPR screens identify dual functions of DNMT3A in mediating tumor immune evasion.Nat Commun2026https://conductscience.org/library/papers/42864360PubMed
42756925m6A-Targeted Cancer Therapy: Molecular Targets, Inhibitors, and Nanodelivery Strategies.Int J Nanomedicine2026https://conductscience.org/library/papers/42756925PubMed
42754163RNA Demethylase FTO Uses Conserved Aromatic Residues to Recognize the mRNA 5' Cap and Promote Efficient m6Am Demethylation.J Biol Chem2026https://conductscience.org/library/papers/42754163PubMed
42729867Metabolic reprogramming and immune evasion interaction in the tumor microenvironment promote tumor progression.Front Oncol2026https://conductscience.org/library/papers/42729867PubMed
42693106Longer-lived mammals exhibit greater evolutionary conservatism and epigenetic modification at cancer-associated loci.Nat Commun2026https://conductscience.org/library/papers/42693106PubMed
42548706Reader-dependent functional duality of FTO: a context-switching node at the intersection of immune evasion and therapeutic resistance.Front Immunol2026https://conductscience.org/library/papers/42548706PubMed
42541138The role, regulatory mechanisms, and therapeutic implications of FTO in gastrointestinal cancer.Genes Dis2026https://conductscience.org/library/papers/42541138PubMed
42527031CXCR2-mediated metabolic interaction between prostate cancer cells and the immunosuppressive tumor microenvironment.J Immunother Cancer2026https://conductscience.org/library/papers/42527031PubMed
42515673m1A and m6A RNA Methylations as Druggable Targets in Cancer.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42515673PubMed
42491192m6A RNA modification: a central epitranscriptomic switch orchestrating oncogenic signaling and glycolytic reprogramming in cancer.Front Cell Dev Biol2026https://conductscience.org/library/papers/42491192PubMed
42488625RNA epitranscriptomic regulation of tumor immune evasion: mechanisms, context-dependent roles, and therapeutic implications.Front Immunol2026https://conductscience.org/library/papers/42488625PubMed
42445445Integrative bioinformatics and experimental analysis identify S100A10 as a diagnostic and prognostic biomarker in pancreatic adenocarcinoma.Transl Cancer Res2026https://conductscience.org/library/papers/42445445PubMed
42435175Influence of RNA Modifications on Cancer Metabolism: Interplay with Hypoxia and Therapeutic Implications.Adv Exp Med Biol2026https://conductscience.org/library/papers/42435175PubMed
42426902Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications.J Hematol Oncol2026https://conductscience.org/library/papers/42426902PubMed
42397900A targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC.Sci Adv2026https://conductscience.org/library/papers/42397900PubMed
42345006RNA Modifications in Tumor Microenvironment: A New Dimension for Cancer Treatment.MedComm (2020)2026https://conductscience.org/library/papers/42345006PubMed
42338603Glycolytic reprogramming in cancer: immune crosstalk, nutrient competition, and supportive care perspectives.Front Immunol2026https://conductscience.org/library/papers/42338603PubMed

See all 242 cited byDownload CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CEBPB1051PubTator's text mininghttps://conductscience.org/library/genes/1051NCBI Gene
FTO79068PubTator's text mininghttps://conductscience.org/library/genes/79068NCBI Gene
GPM6A2823PubTator's text mininghttps://conductscience.org/library/genes/2823NCBI Gene
JUN3725PubTator's text mininghttps://conductscience.org/library/genes/3725NCBI Gene
JUNB3726PubTator's text mininghttps://conductscience.org/library/genes/3726NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33910046

GET https://conductscience.org/api/papers/v1/33910046/cited_by?page=2